Manhattan Scientifics Files 2009 Year End Results

CEO Provides Update On Progress

April 7, 2010

Click here to view the printer friendly version of this press release


NEW YORK--Manhattan Scientifics Inc. (OTCBB: MHTX) will file its Form 10K with the SEC this week, within the permitted 15 day extension period allowed by the SEC.

The company reports several key current items of interest to its 8,500 shareholders. Among the main points are:

  • Our Form 10K will report our first significant increase in revenue
  • Our projection is to be cash-flow positive in 2010
  • Future prospects in our metals business may well exceed plan
  • We have initiated our plan to identify an appropriate Fortune 100 industrial partner within the Medical Devices and Big Pharma industries in order to commercialize our Early Cancer Detection Project

CEO Manny Tsoupanarias stated, "Manhattan Scientifics has had a very successful and active year. Our metals business is running well and on-plan. Manhattan Scientific's Metallicum unit is our core business and its Fortune 1000 industrial partner is providing funding sufficient to cover our entire overhead and cost of all operations, presently and into the foreseeable future.

About Manhattan Scientifics

Manhattan Scientifics, Inc. ( is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.

Forward-looking statement

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.